CISTIM
CISTIM Leuven vzw is a non-profit research organization based in Leuven, Belgium, founded by KU Leuven in 2007. It bridges the gap between academic biomedical research and the pharmaceutical industry, focusing on discovering new medicines through early drug discovery and innovative research. The organization collaborates with biotech companies, academic institutions, and industry partners to develop potential drug candidates addressing critical medical needs.
Industries
Nr. of Employees
small (1-50)
CISTIM
Bioincubator 2, Gaston Geenslaan 2, 3001 Leuven, Belgium
Patents
Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11548881-B2
View Details
Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
US-11548881-B2
View DetailsProducts
Drug discovery project portfolio
A managed portfolio of discovery projects and collaborations (academic and industry) that produce preclinical candidates and translational assets available for further development.
Drug discovery project portfolio
A managed portfolio of discovery projects and collaborations (academic and industry) that produce preclinical candidates and translational assets available for further development.
Services
Collaborative discovery services that include hit identification, medicinal chemistry optimisation, assay development, and preclinical evaluation to generate candidate molecules for partnering or further development.
Maintenance and curation of corporate chemistry and biology databases, chemical registration, inventory management, ELN integration and bespoke data‑extraction queries.
Joint projects with academic labs and industry to validate biological targets and develop biomarkers to enable patient selection and translational decision‑making.
Collaborative discovery services that include hit identification, medicinal chemistry optimisation, assay development, and preclinical evaluation to generate candidate molecules for partnering or further development.
Maintenance and curation of corporate chemistry and biology databases, chemical registration, inventory management, ELN integration and bespoke data‑extraction queries.
Joint projects with academic labs and industry to validate biological targets and develop biomarkers to enable patient selection and translational decision‑making.
Expertise Areas
- Early‑stage drug discovery (small molecules)
- Antiviral discovery and virology
- Medicinal chemistry and lead optimisation
- Cheminformatics and computational chemistry
Key Technologies
- High‑throughput screening (HTS)
- In silico virtual screening and AI‑driven molecular simulation
- Cell‑based and biochemical assay platforms
- In vivo pharmacology models
News & Updates
The Centre for Drug Design and Discovery (CD3) successfully closed a funding round of 70.5 million euros to support biomedical research and drug development.
KU Leuven collaborates with EndLyz Therapeutics to develop therapies for Parkinson's disease and neurodegenerative disorders.
Research uncovers a new strategy to combat coronavirus infections by targeting virus assembly.
The Centre for Drug Design and Discovery (CD3) successfully closed a funding round of 70.5 million euros to support biomedical research and drug development.
KU Leuven collaborates with EndLyz Therapeutics to develop therapies for Parkinson's disease and neurodegenerative disorders.
Research uncovers a new strategy to combat coronavirus infections by targeting virus assembly.